文献速递临床试验与 GCP流行病学与生物统计

SARS-CoV-2大流行期间囊性纤维化临床试验的保护:风险与缓解措施

Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures.
PubMed 文献 · Trials · 2021-08-28

欧洲囊性纤维化学会临床试验网络(ECFS-CTN)通过调查17个欧洲国家的58个试验站点,追踪SARS-CoV-2大流行对临床试验的干扰,并整理缓解措施建议。本文提出通过远程访视、家庭评估、视频电话、电子知情同意和药物家庭配送降低暴露风险,并讨论远程源数据核查、方案修订、站点变更及人员缺勤等实操问题,最后强调通过扩展试验保障患者持续用药。该指南基于网络内站点的共享经验共同制定,并直接分发给所有ECFS-CTN站点。

要点

  • 远程访视、家庭评估和药物家庭配送可降低患者与试验人员的SARS-CoV-2暴露风险。
  • 需应对远程源数据核查、方案修订、站点变更和人员缺勤等实操挑战。
  • 通过扩展试验保障部分患者持续获得研究药物。

核心结论

  • 通过远程访视、家庭评估和药物家庭配送等措施可降低SARS-CoV-2暴露风险并维持试验连续性。
  • 该指南基于ECFS-CTN网络内站点的共享经验制定,可推广至其他疾病临床试验。

研究设计与样本

  • ECFS-CTN对其17个欧洲国家的58个试验站点进行问卷调查,追踪临床试验干扰并整理缓解措施。

主要发现

  • SARS-CoV-2大流行已干扰全球临床试验。
  • ECFS-CTN通过调查58个站点整理了缓解措施和试验连续性信息。

关键数值与推荐

  • 建议尽可能实施远程试验访视,使用家庭评估、视频和电话通话、电子知情同意及研究药物家庭配送。
  • 建议讨论远程源数据核查、方案修订、试验站点位置变更、人员缺勤和家庭工作的实操性。
  • 建议通过扩展试验保障部分患者持续获得研究药物。

临床怎么用

  • 可借鉴远程访视、电子知情同意和药物家庭配送等措施降低暴露风险。
  • 需制定方案修订、远程源数据核查和人员缺勤应对预案以维持试验连续性。
  • 该指南可应用于其他疾病临床试验及无临床试验网络支持的站点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The SARS-CoV-2 pandemic has disrupted clinical trials worldwide. The European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) has tracked clinical trial disruption by surveying its 58 trial sites across 17 European countries and collated information on measures to mitigate the impact of the pandemic and ensure trial continuity. Here, we present recommendations on how to reduce the risk of SARS-CoV-2 exposure to patients and trial staff by implementing remote trial visits where possible, using home assessments, video and phone calls, electronic consent, and home delivery of study drugs. We discuss the practicalities of remote source data verification, protocol amendments, changing trial site location, and staff absences and home working. We outline recommendations on how to protect trial outcomes, including home assessments, safety reporting, protocol deviations, and recruitment challenges. Finally, we discuss the importance of continued access to study drugs via extension trials for some patients. This guidance was co-created from the shared knowledge and experience of sites in our network and was re-distributed directly to all ECFS-CTN sites to help mitigate the impact of further waves of the SARS-CoV-2 pandemic. We will also use this guidance to assist companies, academia, and consortia with future protocol design and risk mitigation plans. This guidance can be applied to clinical trials in other diseases and could help sites that are not supported by clinical trial networks.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. van Koningsbruggen-Rietschel S, Dunlevy F, Bulteel V, et al. Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures. Trials. 2021. PMID: 34454570. doi:10.1186/s13063-021-05457-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。